Literature DB >> 22700003

Pancreatic cancer cells retain the epithelial-related phenotype and modify mitotic spindle microtubules after the administration of ukrain in vitro.

Nicoletta Gagliano1, Tatiana Volpari, Marco Clerici, Letizia Pettinari, Isabella Barajon, Nicola Portinaro, Graziano Colombo, Aldo Milzani, Isabella Dalle-Donne, Carla Martinelli.   

Abstract

The aim of this study is to characterize the phenotype of pancreatic ductal adenocarcinoma (PDAC) cells in relation to the expression of epithelial-to-mesenchymal transition (EMT) markers and determine whether ukrain, an anticancer drug based on the alkaloids extracted from greater celandine, modulates in vitro the malignant behavior of PDAC cells in order to extend our understanding of its therapeutic potential. Three cell lines (HPAF-II, HPAC, and PL45) were treated with ukrain (5, 10, and 20 μmol/l) for 48 h or left untreated (control). Cell proliferation was assessed by growth curves. Apoptosis was determined by Hoechst nuclear staining and by cytochrome c and caspase-8 expressions. The EMT markers E-cadherin, β-catenin, and vimentin, as well as actin and tubulin cytoskeletons, were analyzed by immunofluorescence. Interphase and mitotic microtubules as well as abnormal mitotic figures were studied by fluorescence microscopy after tubulin immunolabeling. Ukrain strongly suppressed cell proliferation and induced apoptosis possibly through an extrinsic pathway as cytochrome c immunoreactivity suggested that the integrity of the mitochondria was not affected. Tubulin expression indicated an antiproliferative effect of ukrain on the basis of alterations in mitotic spindle microtubule dynamics, leading to abnormal mitosis. Membranous E-cadherin/β-catenin immunoreactivity was similarly expressed in control-treated and ukrain-treated cells, although the drug upregulated E-cadherin in cell lysates. Our results suggest that ukrain exerts its chemotherapeutic action on PDAC cells targeting mitotic spindle microtubules, leading to abnormal mitosis and apoptosis, and favoring cell cohesiveness. The differentiated epithelial phenotype of HPAF-II, HPAC, and PL45 cell lines concomitant with a highly invasive potential suggests that further experiments will be necessary to definitively clarify the role of EMT in PDAC progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22700003     DOI: 10.1097/CAD.0b013e32835507bc

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  5 in total

1.  Endogenous Pancreatic Cancer Cell PD-1 Activates MET and Induces Epithelial-Mesenchymal Transition to Promote Cancer Progression.

Authors:  Megan M Harper; Miranda Lin; Shadi A Qasem; Reema A Patel; Michael J Cavnar; Prakash K Pandalai; Mei Gao; Joseph Kim
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

2.  Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma: Characterization in a 3D-cell culture model.

Authors:  Nicoletta Gagliano; Giuseppe Celesti; Lorenza Tacchini; Stefano Pluchino; Chiarella Sforza; Marco Rasile; Vincenza Valerio; Luigi Laghi; Vincenzo Conte; Patrizia Procacci
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

3.  Apoptosis-mediated anticancer activity in prostate cancer cells of a chestnut honey (Castanea sativa L.) quinoline-pyrrolidine gamma-lactam alkaloid.

Authors:  Giangiacomo Beretta; Roberta Manuela Moretti; Rita Nasti; Raffaella Cincinelli; Sabrina Dallavalle; Marina Montagnani Marelli
Journal:  Amino Acids       Date:  2021-05-04       Impact factor: 3.520

4.  Hydroxy-Propil-β-Cyclodextrin Inclusion Complexes of two Biphenylnicotinamide Derivatives: Formulation and Anti-Proliferative Activity Evaluation in Pancreatic Cancer Cell Models.

Authors:  Rosa Maria Iacobazzi; Annalisa Cutrignelli; Angela Stefanachi; Letizia Porcelli; Angela Assunta Lopedota; Roberta Di Fonte; Antonio Lopalco; Simona Serratì; Valentino Laquintana; Nicola Silvestris; Massimo Franco; Saverio Cellamare; Francesco Leonetti; Amalia Azzariti; Nunzio Denora
Journal:  Int J Mol Sci       Date:  2020-09-07       Impact factor: 5.923

Review 5.  Greater Celandine's Ups and Downs-21 Centuries of Medicinal Uses of Chelidonium majus From the Viewpoint of Today's Pharmacology.

Authors:  Sylwia Zielińska; Anna Jezierska-Domaradzka; Magdalena Wójciak-Kosior; Ireneusz Sowa; Adam Junka; Adam M Matkowski
Journal:  Front Pharmacol       Date:  2018-04-11       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.